Akouos

$17.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (+0.57%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Akouos and other stocks, options, and ETFs commission-free!

About AKUS

Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. The listed name for AKUS is Akouos, Inc. Common Stock.

CEO
Emmanuel J. Simons
Employees
54
Headquarters
Boston, Massachusetts
Founded
2016
Market Cap
603.37M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
62.35K
High Today
$18.47
Low Today
$17.39
Open Price
$17.51
Volume
62.12K
52 Week High
$30.67
52 Week Low
$16.59

Collections

AKUS Earnings

-$11.14
-$7.43
-$3.71
$0.00
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 25, Pre-Market

You May Also Like

SPXE
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure